TR-Dizin İndeksli Yayınlar Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/20.500.12573/396
Browse
3 results
Search Results
Research Project Investigation of the Antitumor Effect of Targeting PI3K-AKT-mTOR Pathway and Histone Deacetylase Enzymes on Acute Myeloid Leukemia Cells(2022) Şansaçar, Merve; Akçok, Emel Başak Gencer; Okur, Tuğba; Karaca, MünevverAcute Myeloid Leukemia (AML) is a disease characterized by the accumulation of immature myeloid cells called blasts in the peripheral blood, bone marrow, spleen, and liver, eventually leading to hematopoietic malignancy. In addition to genetic abnormalities, important cellular pathways such as PI3K/AKT/mTOR, Wnt, Notch, STAT3, Hedgehog have been reported to play a role in the pathogenesis of AML. Histone deacetylase (HDAC) inhibitors have promising anticancer activity for AML. In this study, it was aimed to investigate the effect of inhibition of the PI3K/AKT/mTOR pathway and HDAC inhibition on the molecular mechanism underlying this disease using cell lines of different AML subgroups, MOLM-13 and CMK cell lines. For this purpose, the effects of PI3K inhibitor LY294002 and HDAC inhibitors (SAHA, PCI-3501 and Tubastatin A) and their combinations were investigated. Cell proliferation was determined by MTT cell cytotoxicity test and apoptosis rates were determined by Annexin-V/PI double staining method, and the effects of drugs on the cell cycle were determined by PI staining. The level of LC3B protein, a marker of autophagy, was confirmed at the molecular level by western blot. The inhibitors used decreased cell viability at low micromolar concentrations on both cell lines. It was determined that the LY294002+SAHA combination treatment showed a 50% reduction in cell proliferation in MOLM-13 cells and a 25% decrease in CMK cells. LY294002+Tubastatin A treatment has been shown to reduce cell proliferation in MOLM-13 and CMK cells by 65% and 40%, respectively. Our results showed that combinations of LY294002 and HDAC inhibitor resulted in G0/G1 phase arrest in MOLM-13 cells compared to control cells. On the other hand, CMK cells treated with combinations of LY294002+SAHA, LY294002+PCI-3501 and LY294002+Tubastatin A were arrested in G2/M, G2/M and G0/G1 phase, respectively. The effect of the combinations on apoptotic cell death was investigated. LC3B protein expression level was checked as a result of combination therapy. Considering the effects of HDAC enzymes on both AML and different cancers, HDAC inhibition is an important and high-potential target for AML. Therefore, investigation of the PI3K/AKT/mTOR pathway and inhibition of HDACs in different subgroups may provide insight into the mechanisms leading to the pathogenesis of AML. Consequently, it is hoped that this inhibition of PI3K/AKT/mTOR and HDAC will lead to a more specific combination of targeted therapy that results in the abolition of AML.Article Dalak Tirozin Kinaz ve Histon Deasetilaz Enzim İnhibisyonunun FLT3-ITD(+) Akut Miyeloid Lösemi Hücreleri Üzerindeki Anti-Lösemik Etkisi(2025) Akcok, E. Basak Gencer; Şansaçar, MerveSpleen Tyrosine Kinase (Syk) crosstalk with paramount signaling pathways which has a major contribution in the progress of acute myeloid leukemia (AML) such as PI3K, NFκB and JAK/STAT signaling pathways. Several studies recorded that deregulated Histone Deacetylase (HDAC) enzymes are involved in the pathogenesis of AML. The study aims to reveal the effect of Syk and HDAC co-inhibition on MOLM-13 and MV4-11 AML cells which are harboring the receptor of FMS-like Tyrosine Kinase's (FLT3) Internal Tandem Duplication (ITD). AML cells were incubated using both R406 and HDAC inhibitors alone and in combination, and increasing concentrations of R406 and HDAC inhibitors revealed a significant reduction of MOLM-13 and MV4-11 cells’ viability using MTT cell viability test. Furthermore, the combination of R406 and VPA resulted in a reduction in the proliferation of both cells correlated with the synergistic effect of the two drugs revealed by the combination index (CI). Moreover, investigating apoptosis for the combined administration of drugs resulted in induced apoptosis in AML cells using Annexin-V/PI double staining. We observed also changes in the mRNA expression level of MYC after combination treatment via Real-time PCR analysis. Even though further studies are needed, targeting Syk and HDAC enzymes in AML cells may be a good strategy in the treatment of patients suffering from AML with FLT3 ITD (+) mutation.Research Project PI3K-AKT-mTOR Yolağı ve Histon Deasetilaz Enzimlerinin Hedeflenmesinin Akut Myeloid Lösemi Hücreleri Üzerine Antitümör Etkisinin İncelenmesi(2022) Şansaçar, Merve; Akçok, Emel Başak Gencer; Okur, Tuğba; Karaca, MünevverAcute Myeloid Leukemia (AML) is a disease characterized by the accumulation of immature myeloid cells called blasts in the peripheral blood, bone marrow, spleen, and liver, eventually leading to hematopoietic malignancy. In addition to genetic abnormalities, important cellular pathways such as PI3K/AKT/mTOR, Wnt, Notch, STAT3, Hedgehog have been reported to play a role in the pathogenesis of AML. Histone deacetylase (HDAC) inhibitors have promising anticancer activity for AML. In this study, it was aimed to investigate the effect of inhibition of the PI3K/AKT/mTOR pathway and HDAC inhibition on the molecular mechanism underlying this disease using cell lines of different AML subgroups, MOLM-13 and CMK cell lines. For this purpose, the effects of PI3K inhibitor LY294002 and HDAC inhibitors (SAHA, PCI-3501 and Tubastatin A) and their combinations were investigated. Cell proliferation was determined by MTT cell cytotoxicity test and apoptosis rates were determined by Annexin-V/PI double staining method, and the effects of drugs on the cell cycle were determined by PI staining. The level of LC3B protein, a marker of autophagy, was confirmed at the molecular level by western blot. The inhibitors used decreased cell viability at low micromolar concentrations on both cell lines. It was determined that the LY294002+SAHA combination treatment showed a 50% reduction in cell proliferation in MOLM-13 cells and a 25% decrease in CMK cells. LY294002+Tubastatin A treatment has been shown to reduce cell proliferation in MOLM-13 and CMK cells by 65% and 40%, respectively. Our results showed that combinations of LY294002 and HDAC inhibitor resulted in G0/G1 phase arrest in MOLM-13 cells compared to control cells. On the other hand, CMK cells treated with combinations of LY294002+SAHA, LY294002+PCI-3501 and LY294002+Tubastatin A were arrested in G2/M, G2/M and G0/G1 phase, respectively. The effect of the combinations on apoptotic cell death was investigated. LC3B protein expression level was checked as a result of combination therapy. Considering the effects of HDAC enzymes on both AML and different cancers, HDAC inhibition is an important and high-potential target for AML. Therefore, investigation of the PI3K/AKT/mTOR pathway and inhibition of HDACs in different subgroups may provide insight into the mechanisms leading to the pathogenesis of AML. Consequently, it is hoped that this inhibition of PI3K/AKT/mTOR and HDAC will lead to a more specific combination of targeted therapy that results in the abolition of AML.